SpaceX’s $1.75 Trillion Specter Looms as MSCI World ETF Navigates Earnings, Tariffs, and Index Overhaul

The iShares MSCI World ETF is weathering a storm of competing forces. From the imminent debut of Elon Musk’s SpaceX to a flurry of quarterly reports from its top holdings, the $70 billion-plus fund is being pulled in multiple directions. While the technology sector — which accounts for roughly 27% of the portfolio — braces for critical earnings from Alphabet and Microsoft, the financial sector has already delivered a strong performance. Yet the biggest structural shift on the horizon may come from a single listing: SpaceX’s planned Nasdaq debut in June.

A Space Giant Prepares for Liftoff

SpaceX has confidentially filed a registration draft with the US Securities and Exchange Commission, targeting a listing that could raise $75 billion based on a $1.75 trillion valuation. The Nasdaq has already moved to accommodate the behemoth, scrapping its minimum public float requirement and slashing the waiting period for new entrants from three months to just 15 trading days. If the deal proceeds as planned in June, the implications for the MSCI World index are profound. The fund’s sector weighting would shift noticeably toward aerospace and software, potentially reshaping the portfolio’s composition for years to come.

Tesla’s Mixed Bag

Before SpaceX steals the spotlight, the ETF’s current tech heavyweights are delivering their own drama. Tesla reported an adjusted profit of $0.41 per share for the first quarter of 2026, beating expectations, though revenue of $22.39 billion fell slightly short of forecasts. The bright spot was gross margin, which climbed to 21.1% — well above the year-ago figure. The stock initially jumped about 4% in after-hours trading, but those gains quickly evaporated after management announced plans to boost spending by $5 billion this year. With a year-to-date decline of 14%, Tesla remains the worst performer among the Magnificent Seven.

Alphabet and Microsoft Under the Microscope

The spotlight now shifts to Alphabet and Microsoft, both reporting after US markets close on Wednesday. Alphabet enters with unanimous analyst support — not a single sell rating on the stock — but the focus has shifted from revenue growth to profitability. Investors are demanding proof that the company’s near-doubling of capital expenditures is justified. Microsoft, which carries a 3.44% weighting in the portfolio, faces its own challenges. While Azure posted strong growth last quarter, the stock trades well below its all-time high. TD Cowen recently cut its price target to $540, citing GPU infrastructure capacity constraints.

Should investors sell immediately? Or is it worth buying MSCI World ETF?

Banks Deliver, Investors Pile In

While tech plays wait for their moment, the financial sector has already delivered. JPMorgan Chase reported a record trading revenue of $11.6 billion for the first quarter, while Morgan Stanley posted a sharp profit jump. Together, banks make up roughly 16% of the ETF — the second-largest sector weight — and their strong results have attracted fresh capital. Over the past three months, the fund has seen net inflows of about $770 million. Major institutional investors like the Royal Bank of Canada have significantly increased their positions.

Fee War and Dividend Outlook

BlackRock charges 0.24% for the iShares product, a premium to competitors like Invesco and UBS, which offer fees as low as 0.05%. The asset manager defends the spread by pointing to an extremely low tracking difference and high liquidity. The fund has gained 4.2% year-to-date and will trade ex-dividend on June 15, with the market expecting a payout of $2.81 per share over the next twelve months.

Structural Hurdles Ahead

Beyond earnings, the ETF faces two significant structural challenges. In May, MSCI will implement a new methodology for calculating free float, which will increase portfolio turnover for tracking funds. The reform captures equity total return swaps and updates thresholds for European insurers, forcing concrete rebalancing in the coming weeks.

Then in late July, new US tariffs on imported pharmaceuticals are set to take effect. Imports from the EU and Switzerland will face a 15% levy, while British products will be taxed at 10%. The health-care sector, which accounts for nearly 10% of the fund’s assets, is directly threatened. FactSet has already lowered its earnings growth forecast for the S&P 500 in response.